Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sophiris Bio Inc SPHS

Healthcare Biotechnology
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is... see more

Recent & Breaking News (EXPM:SPHS)

5 Stocks Moving After Hours: Earnings, Offerings And Management Shakeups

Benzinga.com  August 22, 2016

Sophiris Bio Announces Proposed Public Offering of Common Shares and Warrants

PR Newswire August 22, 2016

4 Stocks Moving In Monday's After-Hours Session

Benzinga.com  July 25, 2016

10 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  July 19, 2016

Drugs - Generic Stocks Technical Snapshot - Sophiris Bio, Neurocrine Biosciences, Lannett, and Supernus Pharma

PR Newswire June 28, 2016

Mid-Afternoon Market Update: Dow Falls Over 150 Points; Crude Oil Down 2.5%

Benzinga.com  June 10, 2016

8 Biggest Mid-Day Gainers For Friday

Benzinga.com  June 10, 2016

Mid-Morning Market Update: Markets Open Lower; Westlake Chemical To Purchase Axiall For $33/Share

Benzinga.com  June 10, 2016

10 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  June 10, 2016

Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer

PR Newswire June 9, 2016

Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights

PR Newswire May 16, 2016

Sophiris Bio Engages Oppenheimer & Co. to Advise on Strategic Opportunities

PR Newswire May 12, 2016

Sophiris Bio Inc. Announces Closing of Public Offering of $5,000,000

PR Newswire May 11, 2016

Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering

PR Newswire May 6, 2016

Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting

PR Newswire May 5, 2016

Sophiris Bio to Present at Bloom Burton & Co. Healthcare Investor Conference

PR Newswire April 28, 2016

Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights

PR Newswire March 23, 2016

Sophiris Bio to Present at BIO CEO & Investor Conference

PR Newswire February 2, 2016

Sophiris Bio Reports Encouraging Preliminary Data from Phase 2a Proof of Concept Study in Localized Prostate Cancer

PR Newswire January 28, 2016

Sophiris Bio Inc. Potential FDA Decision Around the Corner - Brief Report

Accesswire January 5, 2016